FBXW23 Activators encompass a range of chemical compounds that indirectly enhance the functional activity of FBXW23, primarily through modulating various cellular pathways and protein turnover mechanisms. For instance, Trichostatin A, a histone deacetylase inhibitor, increases histone acetylation, which in turn affects gene expression patterns including those of proteins that interact with FBXW23. This can enhance the ubiquitination activity of FBXW23. Similarly, Forskolin raises intracellular cAMP levels, activating PKA, which influences the ubiquitin-proteasome system, indirectly enhancing FBXW23's role in protein degradation. MG-132, a proteasome inhibitor, prevents protein degradation, thus potentially increasing the substrates available for FBXW23-mediated ubiquitination. On the other hand, LY294002 and Rapamycin modulate the PI3K/AKT/mTOR pathway and mTOR activity, respectively. These alterations in protein synthesis and degradation dynamics offer a broader range of substrates for FBXW23 to act upon.
The activity of FBXW23 is further influenced by compounds that alter various signaling pathways and cellular stress responses. SB203580, a p38 MAPK inhibitor, and U0126, a MEK inhibitor, change cellular signaling in ways that can indirectly increase the variety of proteins available for FBXW23-mediated ubiquitination. Thapsigargin, by disrupting calcium homeostasis, triggers stress responses that can alter the protein landscape, affecting FBXW23's activity. Staurosporine, with its broad kinase inhibitory effects, also leads to changes in protein turnover, potentially benefiting FBXW23's functional role. Additionally, 5-Azacytidine, a DNA methyltransferase inhibitor, changes gene expression patterns, thereby influencing the pool of proteins that FBXW23 could target. Roscovitine, by impacting cell cycle progression, can lead to a shift in protein turnover, presenting new substrates for FBXW23-mediated ubiquitination. Collectively, these activators, by affecting various cellular mechanisms and pathways, indirectly facilitate the enhancement of FBXW23's ubiquitination activity, without necessitating direct interaction with the protein or upregulating its expression.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, enhances FBXW23 activity by increasing histone acetylation. This alteration in chromatin structure affects gene expression, including genes encoding proteins that interact with FBXW23. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates PKA, which can phosphorylate proteins involved in the ubiquitin-proteasome system, indirectly enhancing FBXW23's role in protein degradation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly increases the substrate availability for FBXW23 by preventing the degradation of proteins, which FBXW23 could potentially target for ubiquitination. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, modifies the AKT/mTOR pathway. This alteration can affect protein synthesis and degradation balance, potentially increasing the substrates available for FBXW23-mediated ubiquitination. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a central regulator of cell growth and protein synthesis. This inhibition can lead to altered protein turnover, providing more substrates for FBXW23-mediated ubiquitination. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, alters cellular stress responses. This modulation can impact the types of proteins synthesized or degraded under stress, indirectly influencing FBXW23's ubiquitination targets. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, a MEK inhibitor, shifts cellular signaling pathways, potentially altering the protein landscape in a way that increases substrates for FBXW23-mediated ubiquitination. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin raises intracellular calcium levels, disrupting calcium homeostasis. This can trigger stress responses that alter protein turnover, indirectly affecting FBXW23's role in ubiquitination. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a kinase inhibitor, affects multiple signaling pathways. This broad inhibition can lead to changes in protein turnover, potentially increasing the substrates available for FBXW23-mediated ubiquitination. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, alters gene expression patterns. This can indirectly increase the variety of proteins available for FBXW23-mediated ubiquitination by changing the protein synthesis landscape. | ||||||